The purpose of this study is to demonstrate the technical feasibility of the SERF Catheter and SERF Cardiac Ablation System to eliminate or control ventricular tachycardia (VT)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
Southlake Regional Health Centre
Newmarket, Ontario, Canada
Montreal Heart Institute - Institut de Cardiologie de Montréal
Montreal, Quebec, Canada
Quebec Heart and Lung Institute - Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Canada
Serious Adverse Events that are potentially device-related
Time frame: Within 30 days of ablation
Major Adverse Cardiac Events
MACE will be accessed from time of ablation to time of discharge from hospital following the ablation (generally within 2 days of ablation procedure).
Time frame: Within 2 days after ablation procedure
Non-inducibility of clinical ventricular tachycardia (VT) and/or elimination of clinically relevant scar or channels
Time frame: At completion of ablation procedure
Intraprocedural non-inducibility and/or scar homogenization of target VT
Time frame: At completion of ablation procedure
Elimination of the target VT and/or reduction in number of VT episodes
Time frame: Within first 6 months of ablation procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.